Amgen (AMGN) Shares Repurchased (2009 - 2022)
Amgen (AMGN) recorded quarterly Shares Repurchased of $6.4 billion in Q1 2022, up 340.75% quarter-over-quarter from $1.4 billion in Q4 2021, and up 630.2% on a YoY basis from $871.0 million in Q1 2021.
Amgen (AMGN) Shares Repurchased (2009 - 2022) Analysis & Trends
Amgen's Shares Repurchased history runs 14 years deep, the most recent figure standing at $6.4 billion for Q1 2022.
- In Q1 2022, Shares Repurchased rose 630.2% year-over-year to $6.4 billion; the TTM figure through Dec 2022 stood at $6.4 billion (up 27.84% YoY), while the FY2024 annual figure was $200.0 million, changed N/A from the prior year.
- Shares Repurchased was $6.4 billion for Q1 2022 at Amgen, up from $1.4 billion in the prior quarter.
- In the past five years, Shares Repurchased ranged from a high of $10.7 billion in Q1 2018 to a low of $555.0 million in Q2 2020.
- Historically, Shares Repurchased has averaged $2.4 billion across 5 years, with a median of $1.4 billion in 2021.
- The sharpest annual moves came in 2018 and 2020: Shares Repurchased jumped 1725.43% in 2018, then plunged 77.02% in 2020.
- A 5-year view of Shares Repurchased shows it stood at $2.1 billion in 2018, then sank by 48.49% to $1.1 billion in 2019, then rose by 10.15% to $1.2 billion in 2020, then increased by 19.75% to $1.4 billion in 2021, then jumped by 340.75% to $6.4 billion in 2022.
- The last three Shares Repurchased figures came in at $6.4 billion (Q1 2022), $1.4 billion (Q4 2021), and $1.1 billion (Q3 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | -439.51 Mn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 2.36 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 4.03 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 1.49 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 874.00 Mn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 419.00 Mn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 6.36 Bn |
| Mar 31, 2022 | 6.36 Bn |
| Dec 31, 2021 | 1.44 Bn |
| Dec 31, 2021 | 1.44 Bn |
| Sep 30, 2021 | 1.08 Bn |
| Sep 30, 2021 | 1.08 Bn |
| Jun 30, 2021 | 1.58 Bn |
| Jun 30, 2021 | 1.58 Bn |
| Mar 31, 2021 | 871.00 Mn |
| Mar 31, 2021 | 871.00 Mn |
| Dec 31, 2020 | 1.21 Bn |
| Dec 31, 2020 | 1.21 Bn |
| Sep 30, 2020 | 765.00 Mn |
| Sep 30, 2020 | 765.00 Mn |
| Jun 30, 2020 | 555.00 Mn |
| Jun 30, 2020 | 555.00 Mn |
| Mar 31, 2020 | 961.00 Mn |
| Mar 31, 2020 | 961.00 Mn |
| Dec 31, 2019 | 1.09 Bn |
| Dec 31, 2019 | 1.09 Bn |